Physician profile
Wai-Lam Chan
NPI 1891791877
$3,035.10
in general payments reported to CMS, 2019-2025
27 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $412 · 2021: $462 · 2022: $248 · 2023: $277 · 2024: $495 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $403.37 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $400.96 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $243.95 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $241.63 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.32 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $236.20 | 2019-2025 | Gardasil 9, Capvaxive, Janumet |
| Amgen INC. | $210.02 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $179.05 | 2020-2024 | Linzess, Viberzi |
| Gilead Sciences, INC. | $171.56 | 2019-2025 | |
| Lilly USA, LLC | $133.40 | 2019-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $114.00 | 2020-2025 | |
| Astellas Pharma US INC | $67.56 | 2020-2022 | |
| Exact Sciences Corporation | $52.14 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $47.77 | 2020 | |
| Sanofi Pasteur INC. | $40.63 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $35.74 | 2025 | Pyrukynd |
| Radius Health, INC. | $29.92 | 2020 | |
| Edwards Lifesciences Corporation | $25.43 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Glaxosmithkline, LLC. | $23.79 | 2025 | Arexvy, Shingrix |
| Grifols USA, LLC | $20.80 | 2019 | |
| Vifor Pharma, INC. | $20.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.55 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.91 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.62 | 2019 | |
| Allergan, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wai-Lam Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.